🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Journey Medical Corporation DERM R2K

Healthcare · Drug Manufacturers - Specialty & Generic · United States
https://journeymedicalcorp.com

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

READ MORE ›
$6.31
-21.71% 1Y

Market & Price

Market Cap
$173.74M
Current Price
$6.31
High / Low (52W)
$9.26 / $4.39
Beta
1.03

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$1.13
Price to Book
5.59
P/S
2.69
EV/EBITDA
-85.10
Dividend Yield
-

Profitability & Returns

ROCE
-13.43%
ROE
-36.62%
ROA
-4.49%
Profit Margin
-14.82%
Op Margin
-9.35%
EPS (Latest Qtr)
$-0.08
EPS (TTM)
$-0.37

Balance Sheet & Liquidity

Debt/Equity
0.83
Quick Ratio
1.38
Current Ratio
1.72
Debt
$25.47M
Total Assets
$94.59M
Current Assets
$66.87M
Working Capital
$29.43M

Ownership

Promoter Holding
32.31%
Chg in Prom Hold
-
FII / Inst Holding
55.68%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$171.99M
Total Revenue (TTM)
$64.68M
EBITDA
$-2.02M
Free Cash Flow
$-3.30M
Operating Cash Flow
$-6.70M
Shares Outstanding
21.53M
Gross Margin
65.44%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
-5.66%
Profit 5Y
20.47%
Revenue (YoY)
21.50%
Earnings (YoY)
-

PROS

  • Profit CAGR of 20.5% over 5 years.

CONS

  • Revenue declined at -5.7% CAGR over 5 years.
  • Trading 31.9% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 DERM Journey Medical Corporation R2K 6.31 - $173.74M - -13.43% -36.62% -5.66% 20.47%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 9.45M10.72M15.29M19.61M20.80M18.23M16.04M12.16M16.96M15.28M13.03M14.86M--13.14M15.01M17.63M16.08M15.96M
Cost of Revenue --------------4.79M4.94M5.75M5.44M6.22M
Gross Profit --------------8.35M10.07M11.88M10.64M9.74M
Operating Expenses --------------11.67M12.95M13.40M11.08M11.23M
Operating Income 239.00K585.00K-13.76M-12.65M-888.00K-7.14M-9.49M-9.56M-7.65M17.25M-10.09M-2.93M---3.32M-2.88M-1.53M-443.00K-1.49M
EBITDA ---------------2.10M-1.71M-292.00K774.00K-189.00K
Interest Expense --------------891.00K937.00K937.00K933.00K892.00K
Pretax Income ---------------4.07M-3.74M-2.31M-1.25M-2.23M
Tax Provision --------------060.00K000
Net Income 29.00K268.00K-11.87M-10.65M-1.38M-7.53M-10.08M-10.14M-8.36M16.79M-10.44M-3.36M---4.07M-3.80M-2.31M-1.25M-2.23M
Diluted EPS 0.000.02-1.30-1.16-0.08-0.43-0.57-0.57-0.460.80-0.53-0.17-0.12--0.18-0.16-0.09--0.08
R&D Expense --29.00K718.00K1.27M2.61M2.81M2.03M1.77M2.23M7.88M913.00K842.00K-39.00K-287.00K--

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 44.53M-73.67M79.18M56.13M61.86M
Cost of Revenue --30.77M22.89M20.88M20.92M
Gross Profit --42.89M56.29M35.26M40.93M
Operating Expenses --70.41M55.22M53.48M49.11M
Operating Income 7.85M--27.52M1.07M-18.23M-8.17M
EBITDA ---23.18M1.92M-8.40M-3.33M
Interest Expense --2.02M1.70M2.70M3.70M
Pretax Income ---29.57M-3.63M-14.61M-11.37M
Tax Provision --63.00K221.00K61.00K60.00K
Net Income 5.28M--29.63M-3.85M-14.67M-11.43M
Diluted EPS 0.49-4.32-1.69-0.21-0.72-
R&D Expense -2.74M10.94M7.54M9.86M480.00K

Compounded Sales Growth

5 Years:-5.66%
1 Year:21.50%

Compounded Profit Growth

5 Years:20.47%
1 Year:-

Stock Price Performance

1 Year:-21.71%
6 Months:-19.72%
3 Months:-22.77%
1 Month:+26.20%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -51.91M-105.16M76.85M80.24M94.59M
Current Assets ---77.68M56.45M48.18M66.87M
Cash & Equivalents -8.25M-32.00M27.44M20.30M24.09M
Inventory ---14.16M10.21M14.43M9.62M
Receivables ---28.21M15.22M10.23M29.78M
Total Liabilities -41.61M-88.18M56.50M60.17M62.74M
Current Liabilities -28.06M-66.83M41.87M35.17M37.44M
Long Term Debt ---19.83M14.62M24.88M25.28M
Total Debt ---22.96M14.73M25.08M25.40M
Total Equity 2.75M10.29M-16.98M20.35M20.07M31.85M
Shares Outstanding ---17.77M19.32M22.15M27.14M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 5.13M--13.53M5.24M-9.13M-12.44M
Investing Cash Flow -1.20M--20.00M-5.00M-15.00M0
Financing Cash Flow -487.00K-16.46M-4.80M16.99M16.23M
Capital Expenditure --10.00M-20.00M-5.00M-15.00M-
Free Cash Flow ---33.53M240.00K-24.13M-12.44M
Net Change in Cash ---17.08M-4.56M-7.13M3.79M

Ratios (Annual)

Figures in %.

Metric Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --58.2%71.1%62.8%66.2%
Operating Margin % 17.6%--37.4%1.4%-32.5%-13.2%
Net Margin % 11.9%--40.2%-4.9%-26.1%-18.5%
ROE % 51.3%--174.5%-18.9%-73.1%-35.9%
ROCE % 32.9%--71.8%3.1%-40.5%-14.3%

Shareholding Pattern

Insiders
32.31%
Institutions
55.68%
Public Float
82.25%

Top Institutional Holders

#Holder% HeldSharesValue
1 Wasatch Advisors LP 9.91% 2.13M $13.46M
2 Tang Capital Management, LLC 7.48% 1.61M $10.16M
3 Vanguard Capital Management LLC 5.02% 1.08M $6.83M
4 Blackrock Inc. 4.52% 972.86K $6.14M
5 Opaleye Management Inc. 4.46% 960.00K $6.06M
6 J. Goldman & Co., L.P. 2.32% 500.19K $3.16M
7 Pale Fire Capital SE 2.24% 481.99K $3.04M
8 Geode Capital Management, LLC 2.15% 463.20K $2.92M
9 UBS Group AG 1.81% 390.14K $2.46M
10 Millennium Management Llc 1.78% 383.07K $2.42M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for DERM

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks